AAPP submitted comments supporting the DEA’s proposal to temporarily place concentrated 7-hydroxymitragynine (7-OH) products in Schedule I due to growing concerns about their opioid-like effects, including dependence, withdrawal, overdose, and other serious health risks. AAPP noted that these highly concentrated products are increasingly available online and in retail settings with limited oversight and often contain much higher levels of 7-OH than occur naturally in kratom. AAPP also encouraged the DEA to continue monitoring kratom-derived and other emerging substances and to take appropriate regulatory action when evidence demonstrates a risk to public health.